Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis

BACKGROUND: The nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of agents (angiotensin converting enzyme inhibitors and sodium glucose cotransporter 2 inhibitors) conferring renal protection to patients with diabetic kidney disease. Two recent meta-analyses using t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosal, Samit, Sinha, Binayak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895809/
https://www.ncbi.nlm.nih.gov/pubmed/36742404
http://dx.doi.org/10.3389/fendo.2023.1114894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895809/
https://www.ncbi.nlm.nih.gov/pubmed/36742404
http://dx.doi.org/10.3389/fendo.2023.1114894

Ejemplares similares